<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: Re: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="Re: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-08">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>Re: Performance enhancement with selegiline</h1>
<!-- received="Sat Feb  8 17:43:45 2003" -->
<!-- isoreceived="20030209004345" -->
<!-- sent="Sat, 8 Feb 2003 19:43:40 -0500" -->
<!-- isosent="20030209004340" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="Re: Performance enhancement with selegiline" -->
<!-- id="00b401c2cfd4$4b8837f0$6401a8c0@dimension" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="5.1.1.6.2.20030207230512.00a26ec0@mail.attbi.com" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=Re:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Sat Feb 08 2003 - 17:43:40 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2347.html">Michael Roy Ames: "Re: I am the Google"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2345.html">Adrian Tymes: "Re: I am the Google"</a>
<li><strong>In reply to:</strong> <a href="2304.html">ct: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2308.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2346">[ date ]</a>
<a href="index.html#2346">[ thread ]</a>
<a href="subject.html#2346">[ subject ]</a>
<a href="author.html#2346">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
----- Original Message -----
<br>
From: &quot;ct&quot; &lt;<a href="mailto:tilley314@attbi.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline">tilley314@attbi.com</a>&gt;
<br>
To: &lt;<a href="mailto:extropians@extropy.org?Subject=Re:%20Performance%20enhancement%20with%20selegiline">extropians@extropy.org</a>&gt;
<br>
Sent: Saturday, February 08, 2003 3:51 AM
<br>
Subject: RE: Performance enhancement with selegiline
<br>
<p><p><em>&gt; At 12:56 PM 2/7/2003 -0500, you wrote:
</em><br>
<em>&gt; &gt;gts wrote:
</em><br>
<em>&gt; &gt; &gt; If you were really on top of this subject, Rafal, then I believe you
</em><br>
<em>&gt; &gt; &gt; and I would not be arguing whether selegiline is neuroprotective.
</em><br>
<em>&gt; &gt;
</em><br>
<em>&gt; &gt;### OK, I am just too incompetent to discuss PD with you.
</em><br>
<em>&gt;
</em><br>
<em>&gt; I think it is just a temporary side-effect of off label camaro use!
</em><br>
<p>### Yep, these accelerations can make your eyeballs bounce off the back of
<br>
your skull and cause a repetitive concussion injury :-)
<br>
<p>Thanks for quoting the American Academy of Neurology practice parameters -
<br>
these are the authoritative summaries of available data, and I should have
<br>
mentioned them myself - after all, this is what I try to use in my daily
<br>
practice whenever possible.
<br>
<p>Rafal
<br>
<p><p>-----------------------------
<br>
<p><em>&gt; ====================================================
</em><br>
<em>&gt; PD ~560,000 patients in US
</em><br>
<em>&gt; ~$11billion per annum for PD medication alone
</em><br>
<em>&gt; ====================================================
</em><br>
<em>&gt; Research has shown that levodopa can increase the risk of heart disease in
</em><br>
<em>&gt; Parkinson's patients.
</em><br>
<em>&gt; January 30, 2003 3:58 PM GMT (Datamonitor) - A study published in the
</em><br>
Archives
<br>
<em>&gt; of Neurology suggests a link between levodopa and increased homocysteine
</em><br>
<em>&gt; levels. This new evidence of adverse side effects will increase the demand
</em><br>
for
<br>
<em>&gt; treatments that can delay the need for levodopa.
</em><br>
<em>&gt; ===========================================================
</em><br>
<em>&gt; <a href="http://archneur.ama-assn.org/issues/current/abs/noc20099.html">http://archneur.ama-assn.org/issues/current/abs/noc20099.html</a>
</em><br>
<em>&gt; ...patients with Parkinson disease (PD) may have elevated homocysteine
</em><br>
<em>&gt; levels resulting from methylation of levodopa and dopamine by catechol
</em><br>
<em>&gt; O-methyltransferase, an enzyme that uses S-adenosylmethionine as a methyl
</em><br>
<em>&gt; donor and yields S-adenosylhomocysteine. Since S-adenosylhomocysteine is
</em><br>
<em>&gt; rapidly converted to homocysteine, levodopa therapy may put patients at
</em><br>
<em>&gt; increased risk for vascular disease by raising homocysteine levels...
</em><br>
<em>&gt; Patients whose homocysteine levels were in the higher quartile  had
</em><br>
<em>&gt; increased prevalence of CAD (relative risk, 1.75...
</em><br>
<em>&gt; ===========================================================
</em><br>
<em>&gt; <a href="http://www.aan.com/professionals/practice/pdfs/int_par.pdf">http://www.aan.com/professionals/practice/pdfs/int_par.pdf</a>
</em><br>
<em>&gt; ... Specific questions include:
</em><br>
<em>&gt; 1) does selegiline offer neuroprotection;
</em><br>
<em>&gt; 2) what is the best agent with which to initiate symptomatic treatment in
</em><br>
<em>&gt; de novo PD...
</em><br>
<em>&gt; Using evidence-based principles, a literature review using MEDLINE,
</em><br>
EMBASE,
<br>
<em>&gt; and the Cochrane Library was performed to identify all human trials in de
</em><br>
<em>&gt; novo PD between 1966and 1999. Only articles that fulfilled class I or
</em><br>
class
<br>
<em>&gt; II evidence were included.
</em><br>
<em>&gt;
</em><br>
<em>&gt;   Based on this review, the authors conclude:
</em><br>
<em>&gt; 1) Selegiline has very mild symptomatic benefit (level A, class II
</em><br>
<em>&gt; evidence) with no evidence for neuroprotective benefit(level U, class II
</em><br>
<em>&gt; evidence).
</em><br>
<em>&gt; 2) For PD patients requiring initiation of symptomatic therapy, either
</em><br>
<em>&gt; levodopa or a DA can be used (level A, class I and class II evidence).
</em><br>
<em>&gt; Levodopa provides superior motor benefit but is associated with a higher
</em><br>
<em>&gt; risk of dyskinesia.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Ideally, if a drug were available, initial treatment of PD should slow
</em><br>
<em>&gt; disease progression. Once symptomatic benefit is required, treatment
</em><br>
should
<br>
<em>&gt; reduce disability without inducing complications over the long term.
</em><br>
<em>&gt;
</em><br>
<em>&gt; 4. Dopamine agonists are effective for all features of the disease, but
</em><br>
are
<br>
<em>&gt; not generally as effective as levodopa and are more expensive than
</em><br>
<em>&gt; levodopa(class I, II).
</em><br>
<em>&gt; 5. Selegiline. Class I evidence suggests a mild therapeutic and partial
</em><br>
<em>&gt; protective effect from selegiline,but confirmation of the neuroprotective
</em><br>
<em>&gt; effect is needed. Selegiline also has antidepressant activity that offers
</em><br>
<em>&gt; modest direct symptomatic benefit for PD
</em><br>
<em>&gt;
</em><br>
<em>&gt; The goal of treatment should be to obtain an optimal reduction of
</em><br>
<em>&gt; parkinsonism with a minimal risk of long-term side effects.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Given the controversy generated by the report of Lees et al. that
</em><br>
mortality
<br>
<em>&gt; was increased in patients with PD taking selegiline, studies utilizing
</em><br>
<em>&gt; selegiline in patients already receiving symptomatic therapy were included
</em><br>
<em>&gt; to address the safety of selegiline in this patient population.
</em><br>
<em>&gt;
</em><br>
<em>&gt; Selegiline.What is the role of selegiline in the treatment of early PD?A
</em><br>
<em>&gt; neuroprotective benefit of selegiline through decreased free radical
</em><br>
<em>&gt; production was proposed and resulted in the DATATOP (Deprenyl and
</em><br>
<em>&gt; Tocopherol Antioxidative Therapy of Parkinsonism) clinical trial.
</em><br>
<em>&gt; There is no convincing evidence for increased mortality with selegiline
</em><br>
<em>&gt; whether it is given in combination with levodopa or as monotherapy (class
</em><br>
II).
<br>
<em>&gt;
</em><br>
<em>&gt; Recommendations for patients with PD who require symptomatic treatment
</em><br>
<em>&gt; * Initial symptomatic treatment of patients with PD with selegiline in
</em><br>
<em>&gt; order to confer mild,symptomatic benefit prior to the institution of
</em><br>
<em>&gt; dopaminergic therapy may be considered (level A, class II evidence).
</em><br>
<em>&gt; * There is insufficient evidence to recommend the use of selegiline to
</em><br>
<em>&gt; confer neuroprotection in patients with PD (level U).
</em><br>
<em>&gt;
</em><br>
<em>&gt; Conclusions. Cabergoline, ropinirole, and pramipexole treatment of PD
</em><br>
<em>&gt; patients requiring dopaminergic therapy results in fewer motor
</em><br>
<em>&gt; complications(wearing off, dyskinesias, on-off motor fluctuations)than
</em><br>
<em>&gt; levodopa treatment after 2.5 years of follow-up.Cabergoline, ropinirole,
</em><br>
<em>&gt; and pramipexole treatment of PD patients requiring dopaminergic therapy is
</em><br>
<em>&gt; associated with more frequent adverse events including hallucinations,
</em><br>
<em>&gt; somnolence, and edema than levodopa therapy.
</em><br>
<em>&gt; Recommendations. In patients with PD who require the initiation of
</em><br>
<em>&gt; dopaminergic treatment, either levodopa or a dopamine agonist may be used.
</em><br>
<em>&gt; The choice depends on the relative impact of improving motor disability
</em><br>
<em>&gt; (better with levodopa) compared with the lessening of motor complications
</em><br>
<em>&gt; (better with dopamine agonists) for each individual patient with PD (level
</em><br>
<em>&gt; A,class I and class II evidence).
</em><br>
<em>&gt; =============================================================
</em><br>
<em>&gt; Time for one of those Bayesian network thingees.
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt; [The Maxwell and Dirac equations, for example, govern most of physics and
</em><br>
<em>&gt; all of chemistry and biology. So, in principle we should be able to
</em><br>
predict
<br>
<em>&gt; human behavior, though I can't say I've had much success myself] --Hawking
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2347.html">Michael Roy Ames: "Re: I am the Google"</a>
<li><strong>Previous message:</strong> <a href="2345.html">Adrian Tymes: "Re: I am the Google"</a>
<li><strong>In reply to:</strong> <a href="2304.html">ct: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2308.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2346">[ date ]</a>
<a href="index.html#2346">[ thread ]</a>
<a href="subject.html#2346">[ subject ]</a>
<a href="author.html#2346">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sat Feb 08 2003 - 17:46:06 MST
</em></small></p>
</body>
</html>
